Medicine Man updates revenue for eliminations, announces plan for new name

Denver-based Medicine Man Technologies reduced its pro forma revenue guidance but maintained its pro forma margin and EBITDA guidance via a new presentation filed with the SEC that outlines the story and the vision of the company – including a new name.

Net revenue is lower because of accounting refinements, but EBITDA looks similar to previous estimates and the margins might actually be higher.

The net pro forma revenue will be $144 million after $26 million of revenue eliminations. This means the previous revenue target of $170 million was the gross total of the individual revenue from the target acquisitions.

More importantly, the profitability seems to be basically the same at roughly $35 million of EBITDA.

While the company reiterated its “20-30% EBITDA margin” guidance,

Read Now

Sign inJoin for instant access